Novartis in 1999. Following the historic merger of Sandoz and Ciba, the giant Swiss firm struggled to turn its vision of a life sciences company into a commercial success. As top managers left, its share price suffered. Now Vasella is pushing it back along a familar track, seeking new blockbuster drugs, while making visionary investments in biotech companies as a means, of capturing more new ...
|Year of Publication:||
|Type of Publication:||Article|
|Title record from database:|| OLC-SSG Economic Sciences|
|Availability:||More access options|
|More options (other):|
|Description not available.|